MedTrace Logo

NV-387

Drug

Drug Profile

NV-387 is NanoViricides' investigational broad-spectrum antiviral nanomedicine candidate designed to interfere with a host-side sulfated proteoglycan attachment step used by many viruses. The company is prioritizing Phase II development across MPox and adaptive acute respiratory infection programs, with additional measles and influenza-related plans. The drug remains unapproved and in clinical-stage development.

Drug Class
Investigational broad-spectrum direct-acting antiviral nanomedicine
Approval Status
Investigational; in/planned Phase II development with no approved indication
Mechanism of Action
Host-mimetic sulfated-proteoglycan (S-PG) decoy strategy designed to bind viruses at earliest attachment step and directly attack viral surface
Brand Names
  • NV-387
Indications
  • \MPox infection\
  • \Acute respiratory infections and severe acute respiratory infections (virus-agnostic Phase II programs)\
  • \Additional development plans include measles, RSV, influenza/bird flu, and smallpox-related pathways\

Related News

NanoViricides Files Rare Pediatric Disease and Orphan Drug Applications for NV-387 Against Measles and MPox

NanoViricides has filed regulatory applications for its antiviral candidate NV-387, seeking both Rare Pediatric Disease Drug Designation for measles treatment and Orphan Drug Designation for both measles and MPox treatments. The company could qualify for significant incentives including tax credits, fee exemptions, market exclusivity, and potentially a Priority Review Voucher worth approximately $160 million. There are currently no approved drugs for treating either measles or MPox, with both diseases showing concerning case trends.

Orphan Drugs Market Projected to Reach $486.51 Billion by 2032

The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.